Pharvaris (NASDAQ:PHVS) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Pharvaris (NASDAQ:PHVS) released its earnings results on Thursday. The company reported ($0.77) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.04, Zacks reports.

Pharvaris Stock Performance

NASDAQ PHVS traded down $0.32 during trading hours on Friday, reaching $33.51. The stock had a trading volume of 99,129 shares, compared to its average volume of 452,426. The stock has a fifty day moving average of $33.29 and a 200 day moving average of $31.29. The stock has a market cap of $2.19 billion, a P/E ratio of -10.99 and a beta of -2.48. Pharvaris has a 52-week low of $23.01 and a 52-week high of $43.25.

Insider Activity

In other news, Director Elisabeth Bjork sold 52,500 shares of the firm’s stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $37.89, for a total transaction of $1,989,225.00. Following the sale, the director directly owned 15,167 shares in the company, valued at $574,677.63. This trade represents a 77.59% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, President Peng Lu sold 100,000 shares of the business’s stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $35.00, for a total transaction of $3,500,000.00. Following the sale, the president directly owned 64,953 shares of the company’s stock, valued at $2,273,355. This represents a 60.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 510,810 shares of company stock valued at $18,563,973 over the last 90 days. Company insiders own 11.84% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Wedbush upped their target price on Pharvaris from $42.00 to $50.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 9th. Leerink Partners lifted their price objective on shares of Pharvaris from $50.00 to $65.00 and gave the stock an “outperform” rating in a report on Wednesday, September 9th. New Street Research set a $60.00 price target on Pharvaris in a research report on Friday, August 14th. Wall Street Zen downgraded shares of Pharvaris from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Finally, HC Wainwright reiterated a “buy” rating on shares of Pharvaris in a research note on Tuesday, October 6th. Fourteen analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Pharvaris currently has an average rating of “Moderate Buy” and a consensus target price of $59.53.

About Pharvaris

Pharvaris N.V. is a clinical-stage biopharmaceutical company focused on developing oral treatments for hereditary angioedema (HAE) and other conditions involving bradykinin-mediated swelling. The company was founded in 2015 and is based in Leiden, the Netherlands. Its lead candidate, deucrictibant, is an oral small-molecule antagonist of the bradykinin B2 receptor. Pharvaris is studying the candidate in different formulations for both on-demand treatment of HAE attacks and prevention of attacks.